Cormorant Asset Management’s Acceleron Pharma XLRN Stock Holding History

Cormorant Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-175,000	Closed	-$22M	–	110
2021 Q2	$22M	Sell	175,000 -100,000	-36%	-$12.6M	0.75%	36
2021 Q1	$37.3M	Sell	275,000 -150,000	-35%	-$19.4M	0.83%	30
2020 Q4	$54.4M	Sell	425,000 -75,000	-15%	-$8.79M	1.29%	28
2020 Q3	$56.3M	Sell	500,000 -100,000	-17%	-$9.96M	2.16%	13
2020 Q2	$57.2M	Sell	600,000 -225,000	-27%	-$21.7M	2.18%	16
2020 Q1	$74.1M	Buy	+825,000	New	+$64.1M	3.45%	6
2019 Q4	–	Sell	-25,000	Closed	-$988K	–	85
2019 Q3	$988K	Sell	25,000 -15,000	-38%	-$651K	0.06%	70
2019 Q2	$1.64M	Hold	40,000	–	–	0.09%	68
2019 Q1	$1.86M	Sell	40,000 -8,695	-18%	-$382K	0.13%	62
2018 Q4	$2.12M	Sell	48,695 -1,305	-3%	-$65.2K	0.17%	65
2018 Q3	$2.86M	Sell	50,000 -21,667	-30%	-$1.06M	0.19%	60
2018 Q2	$3.48M	Hold	71,667	–	–	0.26%	50
2018 Q1	$2.8M	Sell	71,667 -3,333	-4%	-$142K	0.21%	47
2017 Q4	$3.18M	Hold	75,000	–	–	0.33%	46
2017 Q3	$2.8M	Hold	75,000	–	–	0.49%	44
2017 Q2	$2.28M	Hold	75,000	–	–	0.38%	56
2017 Q1	$1.99M	Sell	75,000 -52,451	-41%	-$1.38M	0.29%	62
2016 Q4	$3.25M	Hold	127,451	–	–	0.44%	49
2016 Q3	$4.61M	Hold	127,451	–	–	0.51%	53
2016 Q2	$4.33M	Sell	127,451 -72,549	-36%	-$2.36M	0.61%	45
2016 Q1	$5.28M	Hold	200,000	–	–	0.8%	41
2015 Q4	$9.75M	Hold	200,000	–	–	1.17%	32
2015 Q3	$4.98M	Hold	200,000	–	–	0.8%	37
2015 Q2	$6.33M	Buy	200,000 +30,000	+18%	+$968K	0.84%	36
2015 Q1	$6.47M	Sell	170,000 -80,000	-32%	-$3.18M	1%	31
2014 Q4	$9.74M	Sell	250,000 -150,000	-38%	-$5.23M	1.5%	21
2014 Q3	$12.1M	Buy	400,000 +200,000	+100%	+$5.63M	2.49%	9
2014 Q2	$6.79M	Buy	+200,000	New	+$6.69M	1.8%	20

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Cormorant Asset Management's XLRN Position: Q3 2021 in Review

Cormorant Asset Management sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 175,000 shares — an estimated $22M sold.

Cormorant Asset Management first reported a position in XLRN in Q2 2014 and held it in 28 quarters. The position peaked at $74.1M in Q1 2020. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

Cormorant Asset Management reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
Cormorant Asset Management sold 175,000 Acceleron Pharma shares in Q3 2021, an estimated $22M.
Cormorant Asset Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 28 quarters.
Cormorant Asset Management's Acceleron Pharma position peaked at $74.1M in Q1 2020.
330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.